Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.
Abstract
Waldenström macroglobulinemia is an indolent, B-cell lymphoma without a known cure. The bone marrow microenvironment and cytokines both play key roles in Waldenström macroglobulinemia (WM) tumor progression. Only one FDA-approved drug exists for the treatment of WM, Ibrutinib, but treatment plans involve a variety of drugs and inhibitors. This review explores avenues of tumor progression and targeted drug therapy that have been investigated in WM and related B-cell lymphomas.
Department
Open Access Fund; Molecular, Cellular and Biomedical Sciences
Publication Date
1-1-2022
Journal Title
International Journal of Molecular Sciences
Publisher
Multidisciplinary Digital Publishing Institute
Digital Object Identifier (DOI)
Document Type
Article
Recommended Citation
Boutilier, A. J., Huang, L., & Elsawa, S. F. (2022). Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies. International Journal of Molecular Sciences, 23(19), Article 19. https://doi.org/10.3390/ijms231911145
Comments
This is an Open Access article published by Multidisciplinary Digital Publishing Institute in International Journal of Molecular Sciences, available online: https://dx.doi.org/10.3390/ijms231911145